EASL 2024 Winners & Losers
#EASL24 took place this past week
→ One of the biggest liver disease biomed meetings 👇
Which liver smid-caps stocks moved the most during #EASL2024 week*? 🤔
→ See 📸 & below
📈 TOP WINNERS (+)
🟢 AKRO 22%
» Late-breaking presentation, Ph2b HARMONY 96-week data of EFX in patients with MASH. Met primary and add’l histology endpoints.
🟢 TERN 19%
» Wall Street analysts noted potential upside of 136.4%
🟢 CORT 10%
» Presented results of Ph3 GRACE trial at ENDO & HiD
🟢 LPCN 9%
» Presented Ph2 results on LPCN 1148 in cirrhosis
🟢 GNFT 5%
» Data from 2 lead programs in Acute on-Chronic Liver Failure (ACLF)
📉 BIGGEST LOSERS (-)
🔴 ALT -14%
» New data on potential anti-inflammatory and anti-fibrotic properties of pemvidutide in MASH
🔴 HEPA -13%
» Announced in April, wind-down of Ph2 NASH trial due to resource constraints
🔴 SGMT -12%
» Positive data from FASCINATE-2 Ph2b clinical trial of denifanstat vs. placebo in biopsy-confirmed MASH patients
🔴 VKTX -10%
» Met secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 wks of treatment with VK2809.
🔴 ALGS -8%
» Highlighted continued potent antiviral activity of ALG-000184 for chronic hepatitis B in both HBeAg-positive & HBeAg-negative subjects
See tables 📸 for more details! 👇
*Stock price move during week of May 31 - Jun 7
#AKRO #TERN #CORT #LPCN #GNFT #ARWR #IONS #MDGL #ETNB #ZLDPF #MNOV #IVA #ORMP #GALT #CYDY #ALGS #VKTX #SGMT #HEPA #ALT
This article is not investment or legal advice.
Article history:
First published 6/16/24 EJV, AV, DG